LAB150
@lab_150
UTEST's 2021 program applications are now open! In partnership with TIAP - Toronto Innovation Acceleration Partners , we provide #UofT early-stage companies with mentorship, legal expertise, capital and access to networks. #innovation utest.to Applications due by 11:59PM on June 3rd, 2021
A spotlight on the pressing issue of talent in Canadian biotech FedDev Ontario Mélanie Joly François-Philippe Champagne (FPC) 🇨🇦
Congrats to our portfolio co Zucara Therapeutics for initiating its Phase 1b trial. Great to see continuing advances in diabetes being developed by TIAP member University of Toronto right here in Ontario! bit.ly/3l2jwgn FedDev Ontario @TIAPportfolio #diabetes
Very interesting article on amazing scientific sleuthing, and shows the absolute need & reason for strong investment in life sciences. Thanks for sharing, omar carrillo! FedDev Ontario Mélanie Joly #TIAPportfolio
This should be top of the agenda for all parties - and voters. As if the pandemic wasn't reminder enough of the importance of innovation, in life sciences and indeed all areas! FedDev Ontario #lifescienceinnovation #innovationeconomy
Congrats to Vasomune Therapeutics, Inc. on new Phase 2a clinical trial! This portfolio co. was supported through our targeted management programs. Collab with our member Sunnybrook Health Sciences Centre advanced its novel therapeutic strategy to this exciting stage. #lifesciences #TIAPportfolio #covid FedDev Ontario
TIAP portoflio company Zucara Therapeutics awaiting proof-of-concept data to prevent insulin-induced hypoglycemia in people with diabetes biotuesdays.com/2022/02/01/zuc… #diabetes #TIAPportfolio University of Toronto FedDev Ontario
Thank you Wency Leung for your interest in our research.
More good news from TIAP portfolio company Zucara Therapeutics. Positive Phase 1B data provides great promise for preventing hypoglycaemia in diabetic patients. TIAP founded & invested in Zucara based on innovation from University of Toronto: prn.to/3Ow4GKO #diabetes #lifesciences #TIAPportfolio
TIAP portfolio co Zucara Therapeutics is moving their lead program targeting diabetes into Phase II clinical trials. Congratulations to the team and great progress for patients and their families worldwide. Read more here: zucara.ca/news/zucara-th…